EP Patent

EP4238564A1 — New treatments of renal cell carcinoma

Assigned to Bash Biotech Inc · Expires 2023-09-06 · 3y expired

What this patent protects

There is provided a compound or a pharmaceutically acceptable salt or prodrug thereof for use in a method of treatment of a renal cell carcinoma, wherein the compound is selected from the group consisting of TG-101209, panobinostat, NVP-TAE684 and withaferin-a.

USPTO Abstract

There is provided a compound or a pharmaceutically acceptable salt or prodrug thereof for use in a method of treatment of a renal cell carcinoma, wherein the compound is selected from the group consisting of TG-101209, panobinostat, NVP-TAE684 and withaferin-a.

Drugs covered by this patent

Patent Metadata

Patent number
EP4238564A1
Jurisdiction
EP
Classification
—
Expires
2023-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Bash Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.